The newly released Global Swine Vaccine Market analysis report by Future Market Insights reveals that the global market for Swine Vaccine was held at around US$ 1.5 Billion in 2021, and is projected to grow at a CAGR of 5.8% from 2022 to 2032. The market is expected to surge with an absolute dollar opportunity of US$ 1.2 Billion. The projected market growth is expected to cross the historical CAGR of 4.9%.
The Inactivated Vaccines segment is likely to outpace all the other segments by growing at a CAGR of 5.9% from 2022 to 2032. Furthermore, Porcine Circovirus Type 2 was the top type segment in the global market. Revenue through this segment is expected to grow at a CAGR of 5.6% during the forecasted period.
| Attribute | Details |
|---|---|
| Global Swine Vaccines Market (2022) | US$ 1.6 Billion |
| Global Swine Vaccines Market (2032) | US$ 2.8 Billion |
| Global Swine Vaccines Market CAGR (2022 to 2032) | 5.8% |
| USA Swine Vaccines Market CAGR (2022 to 2032) | 6% |
| Key Companies Profiled |
|
The global market for Swine Vaccines is likely to be driven by increased demand for animal protein and surged Research and Development expenditure for vaccine innovation. Swine production is vital to global food security, agricultural countries, and domestic and international trade.
Contagious diseases have a global impact on pig health, as well as the swine industry's stability and production. As a result, increased swine disease prevalence is expected to boost the market in the coming years. Furthermore, leading players' increasing efforts in developing improved products for better diagnostics are expected to drive market expansion.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Swine Vaccine Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Swine Vaccine increased at a CAGR of around 4.9%, while the USA held the majority share of over 35% in the global market.
The market is being driven by increased disease prevalence, increased demand for animal protein, and increased Research and Development expenditure for vaccine innovation. Owing to this, the market for Swine Vaccines is projected to grow at a CAGR of 5.8% during the forecasted period.
Some of the key factors driving the growth of the Swine Vaccine market are the rising prevalence of swine diseases like PPV, Porcine Reproductive and Respiratory Syndrome (PRRS), and Classical Swine Fever, which are likely to cause economic losses due to their negative effects on reproduction and growth in pig farms.
Swine meat is vital for agriculture-based countries and it considerably affects domestic and international trade. Contagious diseases have a global impact on pig health, as well as the swine industry's stability and production. As a result, the increased prevalence of swine disease is expected to boost the market in the coming years.
Putting in place a pig vaccination program helps in protecting them from infectious diseases at every stage of their development. As a result, businesses are concentrating on providing immunization services to assist farmers to manage bacteria and viruses more effectively.
The rise in demand for animal protein, along with rising consumer preferences for a low-fat, high-protein diet like pork has resulted in a significant increase in animal protein consumption around the world.
Principal Consultant
APAC dominated the Swine Vaccine Market, where China led the regional demand. The consumption of beef and pork is higher in middle-income countries, particularly in Southeast Asia.
In addition, emerging infectious diseases in the region, such as swine fever, drive product demand even further. In India, CSF results in an annual loss of approximately 400 crores. As a result, the Indian government is placing a greater emphasis on the development of new vaccines. In October 2019, for example, the ICAR-Indian Veterinary Research Institute developed two diagnostic kits for Swine Control and Antigen Detection. These factors are leading to the expansion of the swine vaccine market in APAC.
USA Swine Vaccine Market Analysis
The market for swine vaccines in the USA is expected to reach a valuation of US$ 319 Million by 2032. With a CAGR of 6% during the forecast period, the market in the country is projected to gross an absolute dollar opportunity of US$ 137 Million.
UK Swine Vaccine Market Analysis
The market in the UK is projected to reach a valuation of US$ 112 Million by 2032. Growing at a CAGR of 6.1% during the forecast period, the market is expected to garner an absolute dollar opportunity of around US$ 48 Million.
China Swine Vaccine Market Analysis
In China, the market is projected to expand at a CAGR of 6.9% during 2022 - 2032. The market in the country is projected to reach US$ 1.1 Billion by 2032, grossing an absolute dollar opportunity of US$ 463 Million during the forecast period.
Japan Swine Vaccine Market Analysis
In Japan, the market is expected to reach a valuation of US$ 224 Million by 2032. With a CAGR of 7.5%, the market in the country is expected to gross an absolute dollar opportunity of US$ 96 Million by 2032.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market for Inactivated Vaccines is gaining the utmost traction and is expected to grow at a CAGR of 5.9% between 2022 and 2032. This increase in growth is attributable to easy availability, low cost, low risk of revert reaction of destroyed viruses, and fresh advances by key companies. For Example, PARVOVAX and PROGRESSIS vaccines were developed to fight against Porcine parvovirus and PRRS.
From 2022 to 2032, the recombinant vaccine category is projected to grow at the fastest rate. Because recombinants can carry many gene inserts, these vaccines are expected to aid in the vaccination of multiple viral strains.
Porcine Circovirus Type 2 is expected to dominate the global market and is expected to grow with a CAGR of 5.6% during the forecast period. PCV2 is the single-stranded DNA having the highest mutation and recombination rate among all single-stranded DNA viruses. It can be spread through an infected pig and is one of the most prevalent infectious agents affecting pig productivity. As a result, during the forecast period, it will contribute to a significant market share.
Some of the key competitors in the Swine Vaccine Market are Merck Animal Health, Ceva, Zoetis, Boehringer Ingelheim GmbH, Elanco, Indian Immunologicals Ltd., BiogénesisBagó, Phibro Animal Health, KM Biologics, and HIPRA.
Some of the recent developments in the Swine Vaccine Market are as follows:
Similarly, recent developments related to companies offering Swine Vaccine have been tracked by the team at Future Market Insights, which are available in the full report.
The Global Swine Vaccine Market is currently valued at US$ 1.5 billion and is expected to reach a valuation of US$ 1.6 billion by the end of 2022.
The Global Market for Swine Vaccine is expected to provide an Absolute Dollar Opportunity of US$ 1.2 billion during the period between 2022 and 2032 by growing at a CAGR of 5.8%.
The Inactivated Vaccines segment is likely to maintain its dominance and is expected to grow at a CAGR of 5.9% during the forecast period. This growth is attributable to easy availability, low cost, low risk of revert reaction of destroyed viruses, and fresh advances by key companies.
The key players operating in the Swine Vaccine market are Merck Animal Health, Ceva, Zoetis, Boehringer Ingelheim GmbH, Elanco, Indian Immunologicals Ltd., BiogénesisBagó, Phibro Animal Health, KM Biologics, and HIPRA.
1. Executive Summary | Swine Vaccine Market 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Demand 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Million) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background and Foundation Data Points 4.1. Global Market (US$ Million) 4.2. Market Opportunity Assessment (US$ Million) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Global Market Growth 4.5.3. Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Market Demand Analysis 2017 to 2021 and Forecast, 2022 to 2032 6.1. Historical Market Analysis, 2017 to 2021 6.2. Current and Future Market Projections, 2022 to 2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Market Value Analysis 2017 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Type, 2017 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Type, 2022 to 2032 8.3.1. Swine Influenza 8.3.2. Classical Swine Fever 8.3.3. Porcine Parvovirus 8.3.4. Porcine Circovirus Type 2 8.3.5. M.Hyo 8.3.6. Actinobacillus Pleuropneumonia 8.3.7. Classical Swine Fever 8.3.8. Foot & Mouth Disease 8.3.9. Pseudorabies 8.3.10. PEDV 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Product, 2017 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2022 to 2032 9.3.1. Attenuated Live Vaccines 9.3.2. Inactivated Vaccines 9.3.3. Subunit Vaccines 9.3.4. DNA Vaccines 9.3.5. Recombinant Vaccines 9.4. Market Attractiveness Analysis By Product 10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 10.1. Introduction 10.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2021 10.3. Current Market Size (US$ Million) & Analysis and Forecast By Region, 2022 to 2032 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. Asia Pacific 10.3.5. Middle East and Africa (MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032 11.1. Introduction 11.2. Pricing Analysis 11.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 11.4.1. By Country 11.4.1.1. United States of America 11.4.1.2. Canada 11.4.1.3. Rest of North America 11.4.2. By Type 11.4.3. By Product 11.5. Market Attractiveness Analysis 11.5.1. By Country 11.5.2. By Type 11.5.3. By Product 12. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 12.4.1. By Country 12.4.1.1. Brazil 12.4.1.2. Mexico 12.4.1.3. Rest of Latin America 12.4.2. By Type 12.4.3. By Product 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Type 12.5.3. By Product 13. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 13.4.1. By Country 13.4.1.1. Germany 13.4.1.2. France 13.4.1.3. United Kingdom 13.4.1.4. Italy 13.4.1.5. Benelux 13.4.1.6. Nordic Countries 13.4.1.7. Rest of Europe 13.4.2. By Type 13.4.3. By Product 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Type 13.5.3. By Product 14. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 14.4.1. By Country 14.4.1.1. China 14.4.1.2. Japan 14.4.1.3. South Korea 14.4.1.4. Rest of Asia Pacific 14.4.2. By Type 14.4.3. By Product 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Type 14.5.3. By Product 15. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 15.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 15.4.1. By Country 15.4.1.1. GCC Countries 15.4.1.2. South Africa 15.4.1.3. Turkey 15.4.1.4. Rest of Middle East and Africa 15.4.2. By Type 15.4.3. By Product 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Type 15.5.3. By Product 16. Key Countries Market Analysis 2017 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.1.1. Market Value Proportion Analysis, By Key Countries 16.1.2. Global Vs. Country Growth Comparison 16.2. US Market Analysis 16.2.1. Value Proportion Analysis by Market Taxonomy 16.2.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.2.2.1. By Type 16.2.2.2. By Product 16.3. Canada Market Analysis 16.3.1. Value Proportion Analysis by Market Taxonomy 16.3.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.3.2.1. By Type 16.3.2.2. By Product 16.4. Mexico Market Analysis 16.4.1. Value Proportion Analysis by Market Taxonomy 16.4.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.4.2.1. By Type 16.4.2.2. By Product 16.5. Brazil Market Analysis 16.5.1. Value Proportion Analysis by Market Taxonomy 16.5.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.5.2.1. By Type 16.5.2.2. By Product 16.6. Germany Market Analysis 16.6.1. Value Proportion Analysis by Market Taxonomy 16.6.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.6.2.1. By Type 16.6.2.2. By Product 16.7. France Market Analysis 16.7.1. Value Proportion Analysis by Market Taxonomy 16.7.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.7.2.1. By Type 16.7.2.2. By Product 16.8. Italy Market Analysis 16.8.1. Value Proportion Analysis by Market Taxonomy 16.8.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.8.2.1. By Type 16.8.2.2. By Product 16.9. BENELUX Market Analysis 16.9.1. Value Proportion Analysis by Market Taxonomy 16.9.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.9.2.1. By Type 16.9.2.2. By Product 16.10. UK Market Analysis 16.10.1. Value Proportion Analysis by Market Taxonomy 16.10.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.10.2.1. By Type 16.10.2.2. By Product 16.11. Nordic Countries Market Analysis 16.11.1. Value Proportion Analysis by Market Taxonomy 16.11.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.11.2.1. By Type 16.11.2.2. By Product 16.12. China Market Analysis 16.12.1. Value Proportion Analysis by Market Taxonomy 16.12.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.12.2.1. By Type 16.12.2.2. By Product 16.13. Japan Market Analysis 16.13.1. Value Proportion Analysis by Market Taxonomy 16.13.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.13.2.1. By Type 16.13.2.2. By Product 16.14. South Korea Market Analysis 16.14.1. Value Proportion Analysis by Market Taxonomy 16.14.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.14.2.1. By Type 16.14.2.2. By Product 16.15. GCC Countries Market Analysis 16.15.1. Value Proportion Analysis by Market Taxonomy 16.15.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.15.2.1. By Type 16.15.2.2. By Product 16.16. South Africa Market Analysis 16.16.1. Value Proportion Analysis by Market Taxonomy 16.16.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.16.2.1. By Type 16.16.2.2. By Product 16.17. Turkey Market Analysis 16.17.1. Value Proportion Analysis by Market Taxonomy 16.17.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.17.2.1. By Type 16.17.2.2. By Product 16.17.3. Competition Landscape and Player Concentration in the Country 17. Market Structure Analysis 17.1. Market Analysis by Tier of Companies 17.2. Market Concentration 17.3. Market Share Analysis of Top Players 17.4. Market Presence Analysis 17.4.1. By Regional footprint of Players 17.4.2. Product footprint by Players 18. Competition Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Competition Deep Dive 18.3.1. Merck Animal Health 18.3.1.1. Overview 18.3.1.2. Product Portfolio 18.3.1.3. Sales Footprint 18.3.1.4. Strategy Overview 18.3.2. Ceva 18.3.2.1. Overview 18.3.2.2. Product Portfolio 18.3.2.3. Sales Footprint 18.3.2.4. Strategy Overview 18.3.3. Zoetis 18.3.3.1. Overview 18.3.3.2. Product Portfolio 18.3.3.3. Sales Footprint 18.3.3.4. Strategy Overview 18.3.4. Boehringer Ingelheim GmbH 18.3.4.1. Overview 18.3.4.2. Product Portfolio 18.3.4.3. Sales Footprint 18.3.4.4. Strategy Overview 18.3.5. Elanco 18.3.5.1. Overview 18.3.5.2. Product Portfolio 18.3.5.3. Sales Footprint 18.3.5.4. Strategy Overview 18.3.6. Indian Immunologicals Ltd 18.3.6.1. Overview 18.3.6.2. Product Portfolio 18.3.6.3. Sales Footprint 18.3.6.4. Strategy Overview 18.3.7. BiogénesisBagó 18.3.7.1. Overview 18.3.7.2. Product Portfolio 18.3.7.3. Sales Footprint 18.3.7.4. Strategy Overview 18.3.8. Phibro Animal Health 18.3.8.1. Overview 18.3.8.2. Product Portfolio 18.3.8.3. Sales Footprint 18.3.8.4. Strategy Overview 18.3.9. KM Biologics 18.3.9.1. Overview 18.3.9.2. Product Portfolio 18.3.9.3. Sales Footprint 18.3.9.4. Strategy Overview 18.3.10. HIPRA 18.3.10.1. Overview 18.3.10.2. Product Portfolio 18.3.10.3. Sales Footprint 18.3.10.4. Strategy Overview 19. Assumptions and Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Swine Vaccine Market
